Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048555 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT00048555 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 90 participants.
The verdict
NCT00048555, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® \[Rituxan® as a single agent is approved by the United States Food and Drug Administration (FDA) to treat patients with relapsed or refractory follicular NHL\], has in this patient population.
Interventions
- DRUG IDEC-114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2002-11 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048555
The ClinicalTrials.gov registry entry for NCT00048555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IDEC-114 is the first listed.
NCT00048555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048555 about?
NCT00048555 is a clinical study titled "Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma". To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® \[Rituxan® as a single agent is approved by the United States Food and Drug Administration (FDA) to treat patients with relapsed or refractory fo...
What is the current status of trial NCT00048555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2002-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00048555?
The interventions under investigation include: IDEC-114 (DRUG).
Who is sponsoring clinical trial NCT00048555?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.